MX2021002909A - Vacunas de proteinas de fusion neumococicas. - Google Patents

Vacunas de proteinas de fusion neumococicas.

Info

Publication number
MX2021002909A
MX2021002909A MX2021002909A MX2021002909A MX2021002909A MX 2021002909 A MX2021002909 A MX 2021002909A MX 2021002909 A MX2021002909 A MX 2021002909A MX 2021002909 A MX2021002909 A MX 2021002909A MX 2021002909 A MX2021002909 A MX 2021002909A
Authority
MX
Mexico
Prior art keywords
fusion protein
protein vaccines
pneumococcal
pneumococcal fusion
vaccines
Prior art date
Application number
MX2021002909A
Other languages
English (en)
Inventor
Richard Malley
Yingjie Lu
Fan Zhang
Original Assignee
Childrens Medical Ct Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Ct Corp filed Critical Childrens Medical Ct Corp
Publication of MX2021002909A publication Critical patent/MX2021002909A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Tecnologías para la prevención y/o tratamiento de infecciones neumocócicas.
MX2021002909A 2018-09-12 2019-09-12 Vacunas de proteinas de fusion neumococicas. MX2021002909A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862730199P 2018-09-12 2018-09-12
PCT/US2019/050800 WO2020056127A1 (en) 2018-09-12 2019-09-12 Pneumococcal fusion protein vaccines

Publications (1)

Publication Number Publication Date
MX2021002909A true MX2021002909A (es) 2021-09-08

Family

ID=69772826

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002909A MX2021002909A (es) 2018-09-12 2019-09-12 Vacunas de proteinas de fusion neumococicas.

Country Status (13)

Country Link
US (2) US20200087361A1 (es)
EP (1) EP3849599A4 (es)
JP (1) JP2022500409A (es)
KR (1) KR20210088535A (es)
CN (1) CN113164580A (es)
AU (1) AU2019338448A1 (es)
BR (1) BR112021004185A2 (es)
CA (1) CA3111436A1 (es)
IL (1) IL281203A (es)
MX (1) MX2021002909A (es)
SG (1) SG11202101973YA (es)
TW (1) TW202035436A (es)
WO (1) WO2020056127A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2900008A1 (en) 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
BR112021004193A2 (pt) 2018-09-12 2021-05-25 Affinivax, Inc. vacinas pneumocócicas multivalentes
WO2023039223A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013028887B1 (pt) * 2011-05-11 2020-10-06 Children's Medical Center Corporation Composição imunogênica apresentando múltiplos antígenos, e métodos e usos dos mesmos
WO2014018904A1 (en) * 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
CA2900008A1 (en) * 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
BR112021004193A2 (pt) * 2018-09-12 2021-05-25 Affinivax, Inc. vacinas pneumocócicas multivalentes

Also Published As

Publication number Publication date
CN113164580A (zh) 2021-07-23
AU2019338448A1 (en) 2021-05-06
SG11202101973YA (en) 2021-03-30
EP3849599A1 (en) 2021-07-21
IL281203A (en) 2021-04-29
TW202035436A (zh) 2020-10-01
US20230089151A1 (en) 2023-03-23
US20200087361A1 (en) 2020-03-19
EP3849599A4 (en) 2022-06-29
CA3111436A1 (en) 2020-03-19
BR112021004185A2 (pt) 2021-05-25
JP2022500409A (ja) 2022-01-04
KR20210088535A (ko) 2021-07-14
WO2020056127A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
PH12021550542A1 (en) Multivalent pneumococcal vaccines
MX2023003461A (es) Tratamiento de infeccion por clostridium difficile.
MX2019013072A (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
CR20230163A (es) ANTICUERPOS ANTITAU Y MÉTODOS DE USO (Divisional 2019-0271)
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
NZ726364A (en) Vaccine composition against streptococcus suis infection
IL281277A (en) Preparations and methods for treating viral infections
MX2019006330A (es) Anticuerpos anti-tau y metodos de uso.
MX2021002909A (es) Vacunas de proteinas de fusion neumococicas.
MX2015016627A (es) Vacuna para la malaria.
MX2020009736A (es) Composiciones que comprenden cepas bacterianas.
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
WO2018136938A8 (en) Induction of protective immunity against antigens
MX2021009105A (es) Toxinas apxia, apxiia y apxiiia inactivadas.
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
EP4011919A3 (en) Relaxin immunoglobulin fusion proteins and methods of use
PL3697405T3 (pl) Nowy inhibitor mek do leczenia zakażeń wirusowych i bakteryjnych
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
PH12019502915A1 (en) Immunogenic compositions
MX2018007408A (es) Uso de adyuvantes para la prevencion y/o el tratamiento de enfermedades autoinmunes.
MX2021004453A (es) Nuevos antigenos y metodos contra el cancer.
EP3747451A4 (en) PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR PNEUMOCOCCIC INFECTION
MX2019013785A (es) Metodos y tratamiento de trauma.